TD Cowen raised the firm’s price target on Waters to $358 from $350 and keeps a Hold rating on the shares. The firm said management comments reflect pharma budgets/orders have firmed and customer feedback supports a pharma demand improvement.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WAT:
